Why This Connecticut Biotech Could be a $1M Opportunity for Investors Post author:Sam Post published:January 23, 2018 Post category:BioPharma Could Cara be the answer for investors itching to make $1 million? Source: BioSpace You Might Also Like Becton, Dickinson and Company Prices Offerings Of $2.25 Billion Of Common Stock And $2.25 Billion Of Depositary Shares Representing Interests In Mandatory Convertible Preferred Stock May 10, 2017 Why Boston-Bound Alexion Could be a Compelling M&A for Larger Drugmakers January 29, 2018 Rumored Acquisition Target Bristol-Myers Squibb Names 3 New Directors, Plans $2 Billion Accelerated Share Buyback February 20, 2017
Becton, Dickinson and Company Prices Offerings Of $2.25 Billion Of Common Stock And $2.25 Billion Of Depositary Shares Representing Interests In Mandatory Convertible Preferred Stock May 10, 2017
Rumored Acquisition Target Bristol-Myers Squibb Names 3 New Directors, Plans $2 Billion Accelerated Share Buyback February 20, 2017
